Insight journal - Company

Alkermes: Specialists in Schizophrenia

Posted on 08 April 2014

Tags: , ,

Alkermes is a Dublin based global biopharmaceutical company developing treatments for CNS disorders including schizophrenia, addiction and depression.

The company has over 20 products on the market, five of which are key commercial products that treat the following indications; multiple sclerosis, schizophrenia, type 2 diabetes and opioid dependence.

Research and development is naturally a big part of the company’s structure and it has brought about a very healthy pipeline of products for the company.  Currently Alkermes has phase three products being developed to treat schizophrenia, Type 2 diabetes and major depressive disorder.  It also has two phase two products being developed for Type 2 diabetes and Schizophrenia. In pre-clinical development two candidates are under development for pain and oncology.

In addition to its drug development capabilities, Alkermes is also a recognized and established provider of contract pharma services. It offers expertise in solid oral dosage product development, scale up and manufacturing amongst others.  In its forty year history it has developed and manufactured over 40 products for some of the world’s biggest pharmaceutical and biotechnology companies including Roche, Pfizer, Novartis, UCB, Abbott and TEVA.

Partnering with top pharma

Alkermes believes that partnerships and collaborations have been responsible for much of its scientific and commercial success as the help of these partnering companies have helped it bring many of its products to the market. Alkermes has worked with the likes of Astrazeneca, Janssen and Acceleron to take products such as RISPERDAL® CONSTA®, INVEGA® SUSTENNA®, AMPYRA® and BYDUREON® to the market.

Alkermes ranks its deep product development expertise and unique capacity to identify and address disease opportunities as some of the main attributes it can offer potential partners who are interested in working with them. The company prides its ability to streamline clinical development which substantially increases late-stage product success.

To contact Alkermes for any potential development ideas or for its contract pharma services you can find a number of contact email addresses on this page. Therapeutically the company is almost certain to be interested in partnering with companies who have CNS related products however from a service point of view the company can develop for any therapeutic area.

Partnering outreach

Alkermes is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.

Events with Alkermes presence include but are not limited to:

  • BIO International Convention and Business Forum
  • BioEurope / BioEurope Spring

For a full list of forthcoming partnering events where you could meet with Alkermes in person visit Current Partnering’s Event calendar.    

Contacting Alkermes for partnering

Alkermes can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:    

Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.

See Current Partnering’s event calendar for details of forthcoming events.   

Direct contact: there are several sources of direct contact with Alkermes’ business development team

-        Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.

-        Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. This page on the Alkermes website has details for contacting Alkermes .

-        LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.

Many of Alkermes’ business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Alkermes Linkedin Page.  

Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the contacts page on the Alkermes website for potential partnering opportunities and general contact names.   

Raveena Bhambra    


Alkermes partnering at Current Agreements

View all partnering deals for Alkermes: 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007

Full details on each deal can be found at CurrentAgreements (subscription required)

Or purchase report: Report: Partnering Agreements with Alkermes 2009-2014


Summary profile data for Alkermes

Partnering activity for Alkermes

M&A activity for Alkermes


Available reports from Current Partnering

Report: Partnering Agreements with Alkermes 2009-2014

Report: Partnering Deals and Alliances with Big Biotech


Available resources for deal coverage for Alkermes      

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Alkermes company profile, recent partnering, M&A and financing news and articles



Report: Finding Biopharma Licensing and Collaboration Partners

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply